As More Products Get Priority Review, User Fee Cost Gap From Standard Review Is Narrowing

 
• By Derrick Gingery

US FDA’s priority review voucher fee will decrease again in FY 2022 as the cost of a priority assessment continues to trend closer to the cost of a standard assessment.

Priority seats
The FDA has been conducting an increasing number of priority assessments of NME NDAs and BLAs in recent years. • Source: Alamy

More from User Fees

More from Pathways & Standards